What Is Tesamorelin?

Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), the endogenous hypothalamic peptide responsible for stimulating the pituitary gland to produce and release growth hormone (GH). Tesamorelin consists of the full 44-amino acid sequence of human GHRH(1–44) with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification is intended to improve metabolic stability relative to endogenous GHRH, which is subject to rapid degradation by serum dipeptidyl peptidase IV (DPP-IV).

Tesamorelin is notable for having achieved regulatory approval in the United States (FDA-approved as Egrifta® for a specific HIV-related lipodystrophy indication) and in Canada (Health Canada-approved under limited indication). This regulatory history makes Tesamorelin a particularly well-characterized peptide in the research literature compared to many other GHRH analogues and research compounds.

In the context of research beyond its approved indication, Tesamorelin is studied for its effects on GH and IGF-1 axis dynamics, body composition parameters in research models, and cognitive endpoints in investigational research. This overview covers Tesamorelin’s scientific background for educational and research-context purposes only. It does not extend to therapeutic guidance, dosage recommendations, or clinical advice.

Chemical Profile and Structure

Tesamorelin is a 44-amino acid peptide with an N-terminal trans-3-hexenoic acid modification. Its full chemical designation reflects this modification, which distinguishes it from native GHRH(1–44).

Key Chemical Characteristics

• Type: Synthetic GHRH analogue (44 amino acids + N-terminal modification)
• Molecular Weight: ~5135.9 Da
• Parent Hormone: Human GHRH (Growth Hormone-Releasing Hormone)
• Modification: Trans-3-hexenoic acid conjugated to N-terminus for DPP-IV resistance
• CAS Number: 218949-48-5
• Physical Form: Lyophilized white powder
• Solubility: Soluble in sterile water and aqueous buffers
• Trade Name (approved formulation): Egrifta® (Theratechnologies)

The N-terminal hexenoic acid modification is the key structural feature that differentiates Tesamorelin from native GHRH. DPP-IV cleaves GHRH at the His-Ala bond between positions 1 and 2, rapidly inactivating it. The N-terminal modification in Tesamorelin resists this cleavage, resulting in a longer-lived molecule in biological systems.

Research Background

The development of Tesamorelin emerged from a broader program at Theratechnologies (a Montreal-based biopharmaceutical company) investigating GHRH analogues for clinical applications. Tesamorelin was specifically developed to address HIV-associated lipodystrophy — a condition involving abnormal fat distribution that was recognized as a significant complication of antiretroviral therapy in HIV-positive individuals.

The development pathway for Tesamorelin is instructive because it represents one of the few cases where a synthetic peptide GHRH analogue successfully navigated the clinical trial process and received regulatory approval. Key milestones include:

• FDA approval (2010) for HIV-associated lipodystrophy (trunk fat reduction)
• Health Canada approval under the brand name Egrifta® for the same indication
• Subsequent research programs investigating Tesamorelin in other metabolic and cognitive contexts

For broader context on GHRH-axis peptides in research, see our comparison of Tesamorelin vs HGH research.

Mechanisms of Interest in Research

Tesamorelin operates through the endogenous GHRH receptor (GHRHR), stimulating pituitary somatotroph cells to produce and secrete growth hormone. Understanding these mechanisms is important for researchers investigating the GH/IGF-1 axis.

GHRH Receptor Activation

Tesamorelin binds to and activates the pituitary GHRH receptor, triggering downstream signalling cascades (including cAMP-PKA pathways) that lead to GH synthesis and secretion. Because Tesamorelin mimics the action of endogenous GHRH rather than administering exogenous GH directly, the GH release occurs within the normal physiological pulsatile pattern, mediated by hypothalamic feedback mechanisms.

IGF-1 Axis Effects

GH released in response to Tesamorelin stimulates hepatic production of Insulin-Like Growth Factor 1 (IGF-1). IGF-1 is a key mediator of many of GH’s anabolic and metabolic effects and is used as a biomarker in research studies examining GH axis activity.

Visceral Adipose Tissue Parameters

The approved indication for Tesamorelin (HIV lipodystrophy) derives from its documented effects on visceral adipose tissue (VAT) in clinical trials. Research has examined this effect across various metabolic and demographic parameters in subsequent investigational studies.

Cognitive Research Parameters

Emerging research has examined whether Tesamorelin’s effects on the GH/IGF-1 axis may have downstream effects on cognitive parameters, particularly in older adults and in populations with HIV-associated neurocognitive challenges. These investigations are ongoing and represent preliminary research findings.

Preclinical and Clinical Research Overview

Tesamorelin has a more extensive clinical research record than most research peptides, given its approved indication. Key research areas include:

HIV-Associated Lipodystrophy Studies

The core Phase III clinical program for Tesamorelin documented statistically significant reductions in visceral adipose tissue in HIV-positive individuals on stable antiretroviral therapy compared to placebo. These trials formed the basis for regulatory approval in both the US and Canada.

Metabolic Research

Post-approval and investigational research has examined Tesamorelin’s effects on triglyceride levels, glucose metabolism, and body composition parameters in various research cohorts beyond the original HIV lipodystrophy indication. Results have been mixed and context-specific.

Cognitive Research Studies

Investigational research programs — most notably work by Dr. Laura Baker and colleagues at Wake Forest University — have examined Tesamorelin’s effects on cognitive function in older adults with mild cognitive impairment. These studies represent early-stage, hypothesis-generating research in a clinical investigation context.

GH Axis Research

Tesamorelin has been used as a research tool to examine GH secretion dynamics, IGF-1 responses, and GHRH receptor pharmacology in various research contexts. It is considered a valuable research compound for GH axis investigations due to its well-characterized receptor specificity and clinical database.

For related compound context, see our overview of CJC-1295 and Ipamorelin, two other peptides studied in GH-axis research contexts.

Tesamorelin in the GHRH Research Context

Several synthetic GHRH analogues and GH secretagogues have been developed and studied for their effects on the GH/IGF-1 axis. Tesamorelin is unique within this class for having achieved regulatory approval, which has allowed for a higher standard of clinical evidence compared to most research peptides.

Other compounds studied in related GH-axis research contexts include:

• CJC-1295: A long-acting GHRH analogue with DAC (Drug Affinity Complex) modification for extended half-life — see What Is CJC-1295?
• Ipamorelin: A selective growth hormone secretagogue that acts via the ghrelin receptor rather than the GHRH receptor — see What Is Ipamorelin?
• CJC-1295 vs Ipamorelin: A comparison of these two complementary research compounds — see CJC-1295 vs Ipamorelin comparison

For a direct comparison of Tesamorelin and exogenous HGH in the research context, see our article: Tesamorelin vs HGH Research Comparison.

Storage and Handling

Tesamorelin, as a large peptide (44 amino acids), requires careful storage to maintain structural integrity for research use. As a lyophilized powder, it is relatively stable but sensitive to improper storage conditions.

Recommended Storage Conditions

• Long-term storage (unreconstituted): 2–8°C (refrigerated) or −20°C for extended storage
• Post-reconstitution: Refrigerated at 2–8°C; use within the timeframe specified in research protocols
• Avoid: Freezing of reconstituted solutions, direct light, elevated temperatures, humidity
• Container: Original sealed vial; minimize headspace exposure after reconstitution

For detailed peptide storage and handling guidance, see our peptide storage guide and peptide reconstitution guide.

Purity and Testing Standards

Given Tesamorelin’s complexity as a 44-amino acid peptide, purity verification is particularly important. Research applications require confirmed identity and high purity to ensure experimental validity.

Standard Testing Methods

• HPLC: Primary purity assessment — research-grade Tesamorelin should achieve ≥98% purity
• Mass Spectrometry: Critical for confirming the correct molecular weight of a 44-amino acid modified peptide and verifying N-terminal modification
• Peptide Content Analysis: Quantifies actual peptide mass vs. total vial weight (accounting for water content in lyophilized powders)

For guidance on evaluating Certificates of Analysis, see what is a CoA? For information on TrueCanPeptides testing standards, see how TrueCanPeptides tests compounds.

Related Research Compounds

• CJC-1295: Long-acting GHRH analogue studied in GH-axis research
• Ipamorelin: GH secretagogue acting via ghrelin receptor pathway
• Metabolic Research Peptides: Overview of peptides studied in metabolic research contexts
• Longevity Research Peptides: Overview of peptides investigated in aging and longevity research

Frequently Asked Questions

Q: What is Tesamorelin?

Tesamorelin is a synthetic GHRH analogue consisting of GHRH(1–44) with an N-terminal trans-3-hexenoic acid modification. FDA-approved and Health Canada-approved as Egrifta® for HIV-associated lipodystrophy, it is also studied in investigational research for GH/IGF-1 axis dynamics and cognitive parameters.

Q: Is Tesamorelin approved in Canada?

Yes, under its approved indication for HIV-associated lipodystrophy as Egrifta®. Outside this approved clinical context, Tesamorelin is an unregistered research compound not available for general therapeutic use.

Q: How does Tesamorelin differ from synthetic HGH?

Tesamorelin stimulates the pituitary to produce GH via the GHRH receptor, preserving physiological pulsatility and feedback regulation. Synthetic HGH (somatropin) delivers exogenous growth hormone directly, bypassing pituitary regulation. See our Tesamorelin vs HGH research comparison for a full breakdown.

Q: What investigational research has been done on Tesamorelin?

Beyond its approved indication, research has examined metabolic parameters, body composition, triglycerides, and cognitive function in older adults with mild cognitive impairment. These are early-stage investigational findings.

Q: How should Tesamorelin be stored for research?

Unreconstituted lyophilized Tesamorelin: store at 2–8°C (refrigerated) or −20°C for extended periods. Reconstituted solutions: refrigerate at 2–8°C and use within protocol-specified timeframes. Do not freeze reconstituted solutions. See our peptide storage guide.

Related Articles

• Tesamorelin vs HGH: Research Comparison
• What Is CJC-1295? Research Overview
• What Is Ipamorelin? Research Overview
• CJC-1295 vs Ipamorelin: Research Comparison
• Peptides for Metabolic Research
• Research Compound Safety and Compliance